EXAS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EXAS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Exact Sciences's Total Stockholders Equity for the quarter that ended in Jun. 2024 was $3,192 Mil. Exact Sciences's Total Assets for the quarter that ended in Jun. 2024 was $6,673 Mil. Therefore, Exact Sciences's Equity to Asset Ratio for the quarter that ended in Jun. 2024 was 0.48.
The historical rank and industry rank for Exact Sciences's Equity-to-Asset or its related term are showing as below:
During the past 13 years, the highest Equity to Asset Ratio of Exact Sciences was 0.93. The lowest was 0.43. And the median was 0.53.
The historical data trend for Exact Sciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Equity-to-Asset | Get a 7-Day Free Trial | 0.65 | 0.45 | 0.51 | 0.49 | 0.49 |
Exact Sciences Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.48 | 0.49 | 0.49 | 0.49 | 0.48 |
For the Diagnostics & Research subindustry, Exact Sciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Exact Sciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Exact Sciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Exact Sciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Equity to Asset (A: Dec. 2023 ) | = | Total Stockholders Equity | / | Total Assets |
= | 3145.305 | / | 6471.334 | |
= | 0.49 |
Exact Sciences's Equity to Asset Ratio for the quarter that ended in Jun. 2024 is calculated as
Equity to Asset (Q: Jun. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 3192.362 | / | 6673.295 | |
= | 0.48 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exact Sciences (NAS:EXAS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Exact Sciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Brian Baranick | officer: Gen. Mgr., Precision Oncology | 441 CHARMANY DRIVE, MADISON WI 53719 |
Jacob A Orville | officer: General Manager, New Ventures | 5505 ENDEAVOR LANE, MADISON WI 53719 |
James Herriott | officer: General Counsel | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Sarah Condella | officer: SVP, Human Resources | 441 CHARMANY DRIVE, MADISON WI 53719 |
D Scott Coward | officer: SVP and General Counsel | 441 CHARMANY DRIVE, MADISON WI 53719 |
Jeffrey Thomas Elliott | officer: Chief Financial Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Kevin T Conroy | director, officer: Vice President | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Everett Cunningham | officer: Chief Commercial Officer | C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094 |
Daniel J Levangie | director | 85 SWANSON ROAD, BOXBOROUGH MA 01719 |
James Edward Doyle | director | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Timothy J Scannell | director | 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002 |
Katherine S Zanotti | director | 431 E 9TH STREET, HINSDALE IL 60521 |
Paul J Clancy | director | C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
Graham Peter Lidgard | officer: SVP, Chief Scientific Officer | 5505 ENDEAVOR LANE, MADISON WI 53719 |
Michael S Wyzga | director | RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, CAMBRIDGE MA 02139 |
From GuruFocus
By Business Wire • 05-07-2024
By Business Wire • 05-24-2024
By Business Wire • 04-11-2024
By GuruFocus Research • 05-24-2024
By Business Wire • 09-16-2024
By Business Wire • 08-20-2024
By GuruFocus Research • 08-28-2024
By GuruFocus Research • 09-16-2024
By GuruFocus Research • 05-09-2024
By GuruFocus Research • 09-19-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.